TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22413962

Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 20135967

Group type: EXPERIMENTAL
Intervention: Indirect decompression (group A)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open decompression (group B)
Number of subjects: 52
Study: 18338276

Group type: EXPERIMENTAL
Intervention: Morphine PCEA combined with lornoxicam 8 mg iv
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine PCEA combined with placebo (saline 2 ml iv)
Number of subjects: 40
Study: 15747892

Group type: EXPERIMENTAL
Intervention: New prostheses (complete dentures)
Number of subjects: 26
Study: 14512205

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15-45 mg (n = 124)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg (n = 122)
Number of subjects: 246
Study: 11033656

Group type: EXPERIMENTAL
Intervention: After-hours nursing care from nurse employees
Number of subjects: 373

Group type: COMPARATOR
Intervention: After-hours nursing care from contract nurses
Number of subjects: 373
Study: 8620226

Group type: EXPERIMENTAL
Intervention: TAC 1 (0.5% tetracaine, 1:2000 adrenaline, 11.8% cocaine)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TAC 2 (1% tetracaine, 1:2000 adrenaline, 4% cocaine)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TAC 3 (1% tetracaine, 4% cocaine without adrenaline)
Number of subjects: 156
Study: 1627434

Group type: EXPERIMENTAL
Intervention: Adjuvant intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) - 600 mg/m2 each of cyclophosphamide and fluorouracil, and 40 mg/m2 of methotrexate, administered IV on day 1, repeated every 3 weeks for a total of 12 treatments.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Local-regional modality alone (control group)
Number of subjects: 90
Study: 2861920

Group type: EXPERIMENTAL
Intervention: 80 mg/day propranolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mg/day metoprolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31779617

Group type: EXPERIMENTAL
Intervention: High fear-avoidance beliefs (FABs) about physical activity (score ≥ 15)
Number of subjects: 3066

Group type: COMPARATOR
Intervention: Low fear-avoidance beliefs (FABs) about physical activity (score < 15)
Number of subjects: 3066
Study: 27893526

Group type: EXPERIMENTAL
Intervention: Supplemental O2 (10 l/min)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 95
Study: 27930743

Group type: EXPERIMENTAL
Intervention: β‐alanine
Number of subjects: 22
Study: 24532523

Group type: EXPERIMENTAL
Intervention: Corticosteroid periarticular injection (40 mg triamcinolone acetonide)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-steroid periarticular injection
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Corticosteroid periarticular injection
Number of subjects: 76
Study: 22443213

Group type: EXPERIMENTAL
Intervention: Insulin detemir (Levemir)
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs (OADs)
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Glinides
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZD)
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 17374
Study: 20876699

Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg kg⁻¹
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg kg⁻¹
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg⁻¹
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg kg⁻¹
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 18728368

Group type: EXPERIMENTAL
Intervention: Miswak impregnated in 3% NaF for 3 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Miswak impregnated in 3% NaF for 1 day
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 g of fluoride toothpaste (1,450 ppm F as NaF)
Number of subjects: 9
Study: 18584262

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight individuals (control)
Number of subjects: 0
Study: 15675646

Group type: EXPERIMENTAL
Intervention: Attending to two nonadjacent regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attending to two distant locations
Number of subjects: 0
Study: 11887299

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study: 9656912

Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory drug gel (2 g, 5% ibuprofen)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Systemic nonsteroidal anti-inflammatory drug tablets (400 mg ibuprofen)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel and placebo tablets
Number of subjects: 10
Study: 8282426

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% Triclosan and 0.75% zinc citrate in a 0.8% sodium monofluorophosphate/silica base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% Triclosan and 0.75% zinc citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice (0.8% monofluorophosphate/silica)
Number of subjects: 0
Study: 2871887

Group type: EXPERIMENTAL
Intervention: Penicillamine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group treatments (excluding penicillamine)
Number of subjects: 73
Study: 11600576

Group type: EXPERIMENTAL
Intervention: Osteopontin mRNA expression during the early secretory phase; maximal expression in mid to late secretory-phase endometrium.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osteopontin expression in epithelial cells; detected in glandular secretions and on the apical portions of surface epithelium.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction of osteopontin expression in response to progesterone.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Up-regulation of beta3 integrin subunit by epidermal growth factor or heparin-binding epidermal growth factor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adhesion assays using Ishikawa cells; alphavbeta3 integrins as primary receptors for osteopontin.
Number of subjects: 0
Study: 31790442

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 29453130

Group type: EXPERIMENTAL
Intervention: Virtual navigation paradigm, Silcton
Number of subjects: 0
Study: 27563176

Group type: EXPERIMENTAL
Intervention: Filtek Z250
Number of subjects: 30

Group type: COMPARATOR
Intervention: P60
Number of subjects: 30
Study: 25319317

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 32

Group type: COMPARATOR
Intervention: Successful smoking cessation group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unsuccessful smoking cessation group
Number of subjects: 32
Study: 22592586

Group type: EXPERIMENTAL
Intervention: 4-week group (tenofovir/lamivudine/efavirenz initiated at 4 weeks of TB treatment)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 12-week group (tenofovir/lamivudine/efavirenz initiated at 12 weeks of TB treatment)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 4-week group
Number of subjects: 156

Group type: COMPARATOR
Intervention: 12-week group
Number of subjects: 156
Study: 20569666

Group type: EXPERIMENTAL
Intervention: Audiological rehabilitation program for SPs (treatment program designed for SPs of PHLs); 90 min sessions, once a week for four weeks.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional group AR program for PHLs; 90 min sessions, once a week for four weeks.
Number of subjects: 72

Group type: COMPARATOR
Intervention: N/A (control SPs received no treatment).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: N/A (experimental SPs participated in treatment program).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: N/A (both groups).
Number of subjects: 72
Study: 18726681

Group type: EXPERIMENTAL
Intervention: 2-back working memory task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Power spectrum analysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coherence analysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cortico-cortical connectivity analysis
Number of subjects: 40
Study: 15772332

Group type: EXPERIMENTAL
Intervention: BERNA-YF
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: RKI-YF
Number of subjects: 304

Group type: COMPARATOR
Intervention: AP-YF
Number of subjects: 304
Study: 11825634

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine
Number of subjects: 248

Group type: COMPARATOR
Intervention: Monovalent hepatitis A and B vaccines
Number of subjects: 248
Study: 10077020

Group type: EXPERIMENTAL
Intervention: OptiMARK (gadoversetamide injection)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Magnevist (gadopentetate dimeglumine)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: OptiMARK
Number of subjects: 193

Group type: COMPARATOR
Intervention: Magnevist
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 193
Study: 7551366

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms twice a day for 2 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2105247

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate started on the 2nd menstrual cycle day (Group A)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Leuprolide acetate started on the 3rd luteal phase day of the preceding IVF cycle (Group B)
Number of subjects: 189
Study: 462303

Group type: EXPERIMENTAL
Intervention: Photographic motion detection (PHOMOT) technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECG-gated radionuclide blood pool scan (GBPS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Photographic techniques developed
Number of subjects: 15
Study: 31088304

Group type: EXPERIMENTAL
Intervention: Oral exercise in addition to standard general care and diet counseling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard general care and diet counseling
Number of subjects: 50
Study: 29652041

Group type: EXPERIMENTAL
Intervention: Pneumatic intermittent compression (PIC) applied with external pressure on the lower extremities at 40-50 mm Hg in wave mode, continuously throughout the daytime for 12-24 hours after stroke.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Graduated compression stockings (GCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myoelectrostimulation (MES)
Number of subjects: 0
Study: 25864403

Group type: EXPERIMENTAL
Intervention: Semantically aligned arithmetic problems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantically misaligned arithmetic problems
Number of subjects: 0
Study: 25074397

Group type: EXPERIMENTAL
Intervention: 7 weeks of supervised physical rehabilitation with progressive strength training (PST)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 7 weeks of supervised physical rehabilitation without progressive strength training (CON)
Number of subjects: 82
Study: 21934634

Group type: EXPERIMENTAL
Intervention: 10 mg S-equol/day (EQL10)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 30 mg S-equol/day (EQL30)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 20495811

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) with 3 cycles of 5 min transient left upper arm ischemia (inflating a blood pressure cuff to 200 mmHg) and 5 min of reperfusion
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 53
Study: 17919544

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.002 mg/kg IV
Number of subjects: 12
Study: 16199794

Group type: EXPERIMENTAL
Intervention: Free fruit and vegetables for 6 months with instruction in meal planning and food preparation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Free fruit and vegetables for 6 months without instruction
Number of subjects: 102

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 102
Study: 14613984

Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 0
Study: 10761749

Group type: EXPERIMENTAL
Intervention: irinotecan
Number of subjects: 256

Group type: COMPARATOR
Intervention: infusional 5-FU
Number of subjects: 256
Study: 8974102

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) diet
Number of subjects: 24
Study: 1456485

Group type: EXPERIMENTAL
Intervention: Siriraj Spacer with 2 puffs of albuterol (100 micrograms/puff)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Volumatic Spacer with 2 puffs of placebo MDI
Number of subjects: 15

Group type: COMPARATOR
Intervention: MDI alone with 2 puffs of placebo MDI
Number of subjects: 15
Study: 6723225

Group type: EXPERIMENTAL
Intervention: Heparin calcium
Number of subjects: 63

Group type: COMPARATOR
Intervention: Heparin sodium
Number of subjects: 63
Study: 31407845

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 819

Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 819

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 819
Study: 28403576

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg on day 1, followed by prasugrel 10 mg once daily on days 2 to 7, then vorapaxar 40 mg and prasugrel 10 mg on day 8, followed by vorapaxar 2.5 mg and prasugrel 10 mg orally once daily on days 9 to 28
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vorapaxar 40 mg on day 1, followed by vorapaxar 2.5 mg once daily on days 2 to 21
Number of subjects: 54
Study: 26674779

Group type: EXPERIMENTAL
Intervention: Ex-PRESS
Number of subjects: 63

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 63
Study: 24668226

Group type: EXPERIMENTAL
Intervention: Prasugrel 100 mg loading dose
Number of subjects: 82

Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose
Number of subjects: 82
Study: 21769989

Group type: EXPERIMENTAL
Intervention: Volunteer-delivered tailored telephone intervention
Number of subjects: 653

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653
Study: 20734480

Group type: EXPERIMENTAL
Intervention: Legalon (herbal product)
Number of subjects: 0
Study: 18592807

Group type: EXPERIMENTAL
Intervention: Project Northland intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (13 schools)
Number of subjects: 26
Study: 15963359

Group type: EXPERIMENTAL
Intervention: Vacc-4x peptide-based therapeutic immunization
Number of subjects: 38
Study: 12555825

Group type: EXPERIMENTAL
Intervention: Starbright World (SBW) - a private, interactive computer network
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard clinical practice condition
Number of subjects: 39
Study: 9671874

Group type: EXPERIMENTAL
Intervention: Liarozole (300 mg two times daily)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA) (100 mg two times daily)
Number of subjects: 321
Study: 8296905

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2725926

Group type: EXPERIMENTAL
Intervention: Sulglicotide (200 mg t.i.d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 4758573

Group type: EXPERIMENTAL
Intervention: Digoxin tablets (0.25 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dissolution rate measurement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: In-vitro dissolution rate measurement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Absorption sensitivity to dissolution rate
Number of subjects: 38
Study: 31305329

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)
Number of subjects: 274

Group type: COMPARATOR
Intervention: ABC/3TC (abacavir/lamivudine)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 274

Group type: COMPARATOR
Intervention: ABC/3TC
Number of subjects: 274
Study: 29221981

Group type: EXPERIMENTAL
Intervention: Chest computed tomography‐guided group (C group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Blind intubation group (B group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27159955

Group type: EXPERIMENTAL
Intervention: Reamberin (1.5% solution, 10 mL/kg body weight intravenously once a day for up to 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional treatment regimen (control group)
Number of subjects: 70
Study: 25326035

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural treatment (10 face-to-face and 9 online sessions)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional face-to-face cognitive behavioural treatment (20 weekly sessions)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blended cognitive behavioural treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional face-to-face cognitive behavioural treatment
Number of subjects: 150
Study: 23173252

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy applied to specific acupoints (Baihui, Shenmen, Shenting, Sanyinjiao, Sishencong) 5 times a week for 8 weeks.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham-acupuncture (5 mm lateral to the acupoints with shallow needling technique) 5 times a week for 8 weeks.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 75
Study: 20595941

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Abdominal hysterectomy (laparotomy)
Number of subjects: 200
Study: 17884602

Group type: EXPERIMENTAL
Intervention: Continuous event recorders (CERs) for 4 weeks
Number of subjects: 244

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 244
Study: 16231999

Group type: EXPERIMENTAL
Intervention: 1 degree step conditioning stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4 degrees step test stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate conditioning stimulus
Number of subjects: 0
Study: 12402727

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (bupivacaine)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Intramuscular meperidine (up to 300 mg)
Number of subjects: 611
Study: 9706926

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 microg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Epidural sufentanil 40 microg after lidocaine with epinephrine test dose
Number of subjects: 70
Study: 7631947

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam 0.05 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1‐0.15 mg.kg‐1)
Number of subjects: 40
Study: 2516707

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (4 micrograms/kg per minute for 3 hours)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Metoclopramide infusion (10 mg as a bolus)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Bromocriptine (5 mg/day for 3 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 925382

Group type: EXPERIMENTAL
Intervention: live attenuated A/Scotland/74 (H3N2) virus vaccine
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 6172176

Group type: EXPERIMENTAL
Intervention: Dextranomer beads (Debrisan)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silicone foam elastomer (Silastic)
Number of subjects: 50
Study: 31182263

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for 12 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: More potent antiplatelet agents (prasugrel and ticagrelor) compared to clopidogrel.
Number of subjects: 0
Study: 30885259

Group type: EXPERIMENTAL
Intervention: Lysulin™ supplementation (two tablets three times a day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 110
Study: 29059197

Group type: EXPERIMENTAL
Intervention: Monthly email reminder intervention for doctors containing a list of patients overdue for a letter.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly described in the abstract).
Number of subjects: 0
Study: 25466663

Group type: EXPERIMENTAL
Intervention: Fitmate metabolic system
Number of subjects: 37

Group type: COMPARATOR
Intervention: Deltatrac II metabolic monitor
Number of subjects: 37
Study: 24804697

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend system active (intervention nights)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Predictive low-glucose suspend system inactive (control nights)
Number of subjects: 45
Study: 22027850

Group type: EXPERIMENTAL
Intervention: Daily stretching (at least 6 times per week)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Stretching 3 times per week
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All stretching groups
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All stretching groups after cessation
Number of subjects: 53
Study: 19570628

Group type: EXPERIMENTAL
Intervention: Hydroxysafflor yellow A (HSYA) 35 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydroxysafflor yellow A (HSYA) 70 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydroxysafflor yellow A (HSYA) 140 mg
Number of subjects: 3
Study: 17517344

Group type: EXPERIMENTAL
Intervention: Systolic heart failure (SHF)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Diastolic heart failure (DHF)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 147